|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 瑞典斯德哥尔摩市社区人群老年痴呆和阿尔茨海默病的危险因素队列研究显示文摘目的探讨老年痴呆和阿尔茨海默病(AD)的危险因素。方法在6年间(1991—1996 年)对斯德哥尔摩市一个社区非痴呆老年人群(n=1301,年龄≥75岁)进行两次随访检查,并按照美国老年精神病协会制订的DSM-Ⅲ-R标准诊断随访期间痴呆和AD新发病例。研究对象在基线调查时对有关因素暴露情况系经问卷调查、临床检查和查阅住院病例登记资料库等方法确定。采用Cox 比例风险模型对资料进行统计分析。结果随访期间共有350例被诊断为痴呆,包括260例AD患者。多因素分析结果显示,痴呆和AD发病的危险因素有年龄大、文化程度低、认知功能损害、体力活动障碍、低舒张压、糖尿病、缺血性心脏病和携带APOEε4基因。脑卒中和心房纤维颤动亦能增加痴呆的危险性,而服用抗高血压药物则可降低痴呆和AD发病的危险性。结论某些人口统计学因素、认知和体力功能障碍、血管性疾病及遗传易感性是老年痴呆和AD的重要危险因素;使用抗高血压药物及控制高血压相关的血管性疾病可能会降低痴呆发病的危险性。 | 仇成轩 Bengt Winblad Laura Fratiglioni | 2005 | 中华流行病学杂志2005，26，11： | 27 |
| 2 | An App knock-in rat model for Alzheimer’s disease exhibiting Aβand tau pathologies,neuronal death and cognitive impairments显示文摘A major obstacle in Alzheimer’s disease(AD)research is the lack of predictive and translatable animal models that reflect disease progression and drug efficacy.Transgenic mice overexpressing amyloid precursor protein(App)gene manifest non-physiological and ectopic expression of APP and its fragments in the brain,which is not observed in AD patients.The App knock-in mice circumvented some of these problems,but they do not exhibit tau pathology and neuronal death.We have generated a rat model,with three familiar App mutations and humanized Aβsequence knocked into the rat App gene.Without altering the levels of full-length APP and other APP fragments,this model exhibits pathologies and disease progression resembling those in human patients:deposit of Aβplaques in relevant brain regions,microglia activation and gliosis,progressive synaptic degeneration and AD-relevant cognitive deficits.Interestingly,we have observed tau pathology,neuronal apoptosis and necroptosis and brain atrophy,phenotypes rarely seen in other APP models.This App knock-in rat model may serve as a useful tool for AD research,identifying new drug targets and biomarkers,and testing therapeutics. | Keliang Pang Richeng Jiang Wei Zhang Zhengyi Yang Lin-Lin Li Makoto Shimozawa Simone Tambaro Johanna Mayer Baogui Zhang Man Li Jiesi Wang Hang Liu Ailing Yang Xi Chen Jiazheng Liu Bengt Winblad Hua Han Tianzi Jiang Weiwen Wang Per Nilsson Wei Guo Bai Lu | 2022 | Cell Research2022，32，2： | 6 |
| 3 | Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study显示文摘 | Bengt Winblad Niels Andreasen Lennart Minthon Annette Floesser Georges Imbert Thomas Dumortier R Paul Maguire Kaj Blennow Joens Lundmark Matthias Staufenbiel Jean-Marc Orgogozo Ana Graf | 2012 | Lancet Neurology2012，，7： | 3 |
| 4 | Revised NIA-AA criteria for the diagnosis of Alzheimer’s disease: a step forward but not yet ready for widespread clinical use显示文摘 | Giovanni B. Frisoni Bengt Winblad John T. O’Brien | 2011 | International Psychogeriatrics2011，，8： | 2 |
| 5 | Clinical trials and late‐stage drug development for A lzheimer’s disease: an appraisal from 1984 to 2014显示文摘 | L. S. Schneider F. Mangialasche N. Andreasen H. Feldman E. Giacobini R. Jones V. Mantua P. Mecocci L. Pani B. Winblad M. Kivipelto | 2014 | J Intern Med2014，，： | 2 |
| 6 | 多奈哌齐治疗重度阿尔茨海默病患者:双盲、平行分组、安慰剂对照研究显示文摘Background: The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer’s disease. Its efficacy in severe dementia has not been assessed and is controversial. Our aim was to ascertain the effectiveness of donepezil in patients with severe Alzheimer’s disease, by focusing primarily on cognition and activities of daily living. Methods: We did a 6-month, double-blind, parallel-group, placebo-controlled study in 248 patients with severe Alzheimer‘s disease (mini mental state examination score 1-10) who were living in assisted care nursing homes ran by trained staff in Sweden. We assigned patients oral donepezil (5 mg per day for 30 days then up to 10 mg per day thereafter, n=128) or matched placebo (n=120). Our primary endpoints were change from baseline to month 6 in the severe impairment battery (SIB) and modified Alzheimer’s Disease Cooperative Study activities of daily living inventory for severe Alzheimer’s disease (ADCS-ADL-severe). We analysed outcomes for patients with data at baseline and at one or more other timepoints (modified intent-to-treat population) with last observation carried forward used to replace missing data. Findings: 95 patients assigned donepezil and 99 patients assigned placebo completed the study. Patients treated with donepezil improved more in SIB scores and declined less in ADCS-ADL-severe scores at 6 months after initiation of treatment compared with baseline than did controls (least squares [LS] mean difference, 5.7, 95%CI 1.5-9.8; p=0.008, and 1.7, 0.2-3.2; p=0.03, respectively). The incidence of adverse events was comparable between groups (donepezil 82%[n=105] vs placebo 76%[n=91]), with most being transient and mild or moderate in severity. More patients discontinued treatment because of adverse events in the donepezil group (n=20) than in the placebo group (n=8). Interpretation: Donepezil improves cognition and preserves function in individuals with severe Alzheimer’s disease who live in nursing homes. | Winblad B. Kilander L. Eriksson S. 周永(译) | 2006 | 世界核心医学期刊文摘(神经病学分册)2006，2，9： | 2 |
| 7 | Nicotinic and muscarinic subtypes in the human brain:Changes with aging and dementia显示文摘 | Nordberg A Alafuzoff I Winblad B | 1992 | J Neurosci Res1992，31，1： | 1 |
| 8 | Economic aspects on drug therapy of dementia显示文摘 | Wimo A Winblad B | 2004 | Curr Pharm Des2004，10，3： | 1 |
| 9 | Alcohol consumption and incidence of dementia in a community sample aged 75 years and older显示文摘 | Huang W Qiu C Winblad B | 2002 | J Clin Epidemiol2002，55，10： | 1 |
| 10 | The age-dependent relation of blood pressure to cognitive function and dementia显示文摘 | Qiu C Winblad B Fratiglioni L | | 0，，08： | 1 |
| 11 | Alzheimer's disease:clinical trials and drug development显示文摘 | Mangialasche F Solomon A Winblad B | | 0，，07： | 1 |
| 12 | Atrial fibrillation,stroke and dementia in the very old:a population-based study显示文摘 | Marengoni A Qiu C Winblad B | 2011 | Neurobiol Aging2011，32，7： | 1 |
| 13 | The magnitude of dementia occurrence in the world显示文摘 | Winblad B Aguero-Torres H | 2003 | Alzheimer Dis Assoc Disord2003，17，2： | 1 |
| 14 | Environmental in- fluences on brain neurotrophins in rats 显示文摘 | Pham TM Winblad B Granholm AC | 2002 | Pharmacol Biochem Behav2002，73，1： | 1 |
| 15 | Cerebrovaseular disease, ApoE e4 allele and cognitive decline in a cognitively normal population 显示文摘 | Qiu c Winblad B Fratiqlioni L | 2006 | Neurol Res2006，28，： | 1 |
| 16 | Mild cognitive impairment?beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment显示文摘 | Winblad B Palmer K Kivipelto M | 2004 | J Inter Med2004，256，3： | 1 |
| 17 | Mild cognitive impairment-beyond controversies,towards a consensus:report of the International Working Group on Mild Cognitive Impairment显示文摘 | Winblad B Palmer K Kivipeho M et a/ | 2004 | Intern Med2004，256，： | 1 |
| 18 | Accumulation of cyclin-de- pendent kinase 5 (cdk5) in neurons with early sta- ges of Alzheimer's disease neurofibrillary degenera- tion显示文摘 | Pei J J Grundke-lqbal I Iqbal K Bogdanovic N Winblad B Cowburn RF | 1998 | Brain Res1998，797，2： | 1 |
| 19 | Mild cognitive impairment–beyond controversies towards a consensus:report of the International Working Group on Mild Cognitive Impairment显示文摘 | Winblad B Palmer K Kivipelto M | 2004 | J Intern Med2004，256，24： | 1 |
| 20 | Therapeutic useof nicergoline显示文摘 | Winblad B Fioravanti M Dolezal T | 2008 | Clinical drug investigation2008，28，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员